Analytical Data
-
Gene name
RLN3
- Application
-
Alternative Names
RLN3；GPCR135；RLN3R1；SALPR；Relaxin-3 receptor 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8WXF3
-
Expression Region
26-52aa
-
AA Sequence
RAAPY GVRLCGREFI RAVIFTCGGS RW
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Recombinant RLN3 protein research has garnered significant attention due to its potential implications in neurobiology and therapeutics. RLN3, or Relaxin-3, is a member of the relaxin family of peptides, primarily expressed in the central nervous system, particularly in the brain and spinal cord. It plays a pivotal role in various physiological processes, including neuroendocrine regulation, stress response, appetite control, and cognitive functions. The interest in RLN3 has been fueled by its unique signaling pathway, which involves the relaxin family peptide receptors, particularly RXFP3 and RXFP4, leading to diverse biological effects. Studies have shown that RLN3 can influence neuroplasticity and may be linked to neurodegenerative diseases, making it a potential target for drug development. The production of recombinant RLN3 proteins allows for detailed studies of its structure-function relationships, receptor interactions, and the underlying molecular mechanisms governing its physiological roles. Furthermore, the recombinant technology enables the exploration of RLN3 as a therapeutic agent for conditions such as depression, anxiety, and metabolic disorders. By characterizing RLN3 through recombinant forms, researchers aim to uncover novel insights into its biological significance and therapeutic potential, ultimately paving the way for innovative treatments targeting RLN3-related pathways.
